Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Ascending Cholangitis in a Patient With Remote Cholecystectomy
Wu, Tiffany , Law, Ryan , Abimansour, Jad, Wu, Tiffany , AbiMansour, Jad P.

American Journal of Gastroenterology | July 8, 2024 | Volume: 120 | Issue: 2 | Pages: 280-280

10.14309/ajg.0000000000002943 | PMID 39073346 Get It

Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis
Magahis, Patrick T. , Chhoda, Ankit , Berzin, Tyler M. , Farrell, James J. , Wright, Drew , Rizvi, Anam, Hanscom, Mark , Carr-Locke, David L., Sampath, Kartik, Sharaiha, Reem Z. , Mahadev, SriHari , Wright, Drew N , Berzin, Tyler M , Carr‐Locke, David L.

American Journal of Gastroenterology | July 8, 2024 | Volume: 119 | Issue: 11 | Pages: 2174-2186

10.14309/ajg.0000000000002942 | PMID 38976379 Get It

INTRODUCTION: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is frequently used to risk-stratify pancreatic cystic lesions (PCLs). Rising PCL incidence and developments in tissue acquisition and specimen analysis necessitate updated appraisal of EUS-FNA safety, particularly the risk of postprocedure pancreatitis, the most common EUS-FNA-related adverse event. Our systematic review aims to accurately quantify the risk of EUS-FNA-related pancreatitis to best inform decisions regarding EUS-FNA's optimal role in PCL workup. METHODS: We performed systematic searches in 4 databases from inception to April 2024 for original English-language studies investigating EUS-FNA-related pancreatitis. We extracted data on demographics and EUS-FNA-related pancreatitis risk, severity, and risk factors. These were meta-analyzed through the DerSimonian Laird Method using a random-effects model. Meta-regression of pancreatitis risk was performed to delineate associations with clinical and procedural characteristics. RESULTS: Sixty-four studies comprised 8,086 patients and reported 110 EUS-FNA-related pancreatitis events. Pooled risk of EUS-FNA-related pancreatitis was 1.4% (95% confidence intervals, −0.8% to 3.5%; I 2 = 0.00), which was predominantly of mild severity (67%) and uniformly nonfatal. Pancreatitis risk lacked significant association with sample size, age, sex, cyst size, needle caliber, or passes, although we noted trends toward higher risk in studies published after 2015, those using higher gauge needles (19 G vs 22 G/25 G), and those performing EUS-guided through-the-needle biopsy. DISCUSSION: We note with high certainty that pancreatitis after EUS-FNA of PCLs is infrequent and mild in severity with no mortality in the included cohort. EUS-guided through-the-needle biopsy may serve as a significant risk factor for EUS-FNA-related pancreatitis risk; however, further studies are needed to delineate other predisposing characteristics.
Fatty Infiltration, Tear Size, and Retraction Size Are Significant Risk Factors for Retear After Arthroscopic Rotator Cuff Repair: A Systematic Review
Darbandi, Azad J., Credille, Kevin , Darbandi, Aria , Hevesi, Mario , Dandu, Navya , Bodendorfer, Blake M. , Wang, Zachary , Garrigues, Grant E. , Verma, Nikhil N. , Yanke, Adam B. , Hevesi, Mario , Darbandi, Azad

Arthroscopy | July 8, 2024 | Volume: 41 | Issue: 5 | Pages: 1649

10.1016/j.arthro.2024.06.040 | PMID 38986851 Get It

Purpose To assess the consistency and quality of risk factor reporting for rotator cuff repair (RCR) retear and identify risk factors most frequently associated with retear. Methods A systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Of the initial 3,158 studies, a total of 31 met the following inclusion criteria: (1) clinical studies regarding RCR failure, (2) arthroscopic procedures involving RCR, (3) reporting of clinical outcomes, (4) publication within the past 5 years, and (5) studies investigating preoperative risk factors for retear. After full‐text review, 18 risk factors were analyzed. Results The most consistently significant risk factors were acromiohumeral distance (80%), critical shoulder angle (67%), tear size (63%), anterior‐posterior dimension (60%), fatty infiltration (FI) (58%), and retraction size (56%). FI was analyzed using different methods among studies, with 63% finding significant results and 50% of all studies performing ordinal analysis. Tear size was inconsistently analyzed quantitatively or qualitatively, with 58% of studies finding significant results and 63% of all studies performing quantitative analysis. Risk factors consistently found to be nonsignificant included age, sex, diabetes mellitus, symptom duration, hand dominance, repair technique, smoking, and body mass index. Conclusions Tear size, FI, and retraction size were found to be significant risk factors in most of the included studies evaluating rotator cuff retear. Risk factors less likely reported as predictive included repair technique, age, sex, diabetes mellitus, symptom duration, hand dominance, repair technique, smoking, and body mass index. Risk factors that require further investigation include critical shoulder angle, acromiohumeral distance, and anterior‐posterior tear dimension. Level of Evidence Level III, systematic review of Level III‐IV studies.
Mental Health and Autosomal Dominant Polycystic Kidney Disease: A Narrative Review
Ebrahimi, Niloufar , Chebib, Fouad T. , Sparks, Matthew A. , Lerma, Edgar V. , Golsorkhi, Mohadese , Ghozloujeh, Zohreh Gholizadeh , Abdipour, Amir , Norouzi, Sayna , Garimella, Pranav S , Chebib, Fouad T , Sparks, Matthew A , Lerma, Edgar V , Golsorkhi, Mohadese , Ghozloujeh, Zohreh Gholizadeh , Abdipour, Amir , Norouzi, Sayna , Garimella, Pranav S.

Kidney360 | July 8, 2024 | Volume: 5 | Issue: 8 | Pages: 1200-1206

10.34067/kid.0000000000000504 | PMID 38976329 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder marked by the development of cysts in the kidneys and other organs, leading to diverse clinical manifestations, including kidney failure. The psychological burden of ADPKD is substantial, with significant contributors including pain, daily life disruptions, depression, anxiety, and the guilt associated with transmitting ADPKD to offspring. This review details the psychological impacts of ADPKD on patients, addressing how they navigate physical and emotional challenges, including pain management, genetic guilt, mood disorders, and disease acceptance. This review also underscores the need for comprehensive research into the psychological aspects of ADPKD, focusing on the prevalence and contributing factors of emotional distress and identifying effective strategies for managing anxiety and depression. Furthermore, it highlights the importance of understanding the diverse factors that influence patients' quality of life and advocates for holistic interventions to address these psychological challenges.
Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study
Kochhar, Gursimran , Khataniar, Himsikhar , Jairath, Vipul , Farraye, Francis A. , Desai, Aakash , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Farraye, Francis A , Jairath, Vipul , Desai, Aakash , Khataniar, Himsikhar

American Journal of Gastroenterology | July 8, 2024 | Volume: 119 | Issue: 12 | Pages: 2471-2479

10.14309/ajg.0000000000002947 | PMID 38976357 Get It

INTRODUCTION: There are limited real-world data comparing the effectiveness of upadacitinib and tofacitinib in patients with ulcerative colitis (UC). METHODS: We conducted a retrospective cohort study using TriNetX, a multi-institutional database, to compare the effectiveness of upadacitinib and tofacitinib in patients with UC. The primary aim was to assess the risk of a composite outcome of hospitalization requiring intravenous steroids and/or colectomy within 6 and 12 months. One-to-one propensity score matching was performed for demographics, comorbid conditions, mean hemoglobin, C-reactive protein, albumin, and calprotectin, and prior UC medications including recent oral or intravenous steroid use between the cohorts. Risk was expressed as adjusted odds ratio (aOR) with 95% confidence intervals (CI). RESULTS: There were 526 patients in the upadacitinib cohort (mean age 40.4 ± 16.3, 44.8% female sex, 76.6% White race) and 1,149 patients in the tofacitinib cohort (mean age 42 ± 17.1, 41.9% female sex, 76% White race). After propensity score matching, there was no significant difference in the risk of the composite outcome of need for intravenous steroids and/or colectomy within 6 months (aOR 0.75, 95% CI 0.49–1.09). However, there was a lower risk of the composite outcome (aOR 0.63, 95% CI 0.44–0.89) in the upadacitinib cohort compared with the tofacitinib cohort within 12 months. There was no difference in the risk of intravenous steroid use (aOR 0.70, 95% CI 0.48–1.02) but lower risk of colectomy (aOR 0.46, 95% CI 0.27–0.79). In sensitivity analysis, there was also a lower risk of the composite outcome (aOR 0.64, 95% CI 0.44–0.94), including lower risk of intravenous steroid use (aOR 0.67, 95% CI 0.45–0.99) and colectomy (aOR 0.49, 95% CI 0.26–0.92) in the upadacitinib cohort compared with the tofacitinib cohort within 12 months. DISCUSSION: This study utilizing real-world data showed that upadacitinib was associated with improved disease-specific outcomes at 12 months compared with tofacitinib in patients with UC.
Predicting Response to Neuromodulators or Prokinetics in Patients With Suspected Gastroparesis Using Machine Learning: The “BMI, Infectious Prodrome, Delayed GES, and No Diabetes” Model
Takakura, Will , Surjanhata, Brian , McCallum, Richard W. , Schulman, Michael I., Wo, John M. , Sarosiek, Irene , Moshiree, Baha , Lee, Allen , Hasler, William L. , Lee, Allen A , Nguyen, Linda Anh B. , Parkman, Henry P. , Rao, Satish S.C. , Kuo, Braden

Clinical and Translational Gastroenterology | July 8, 2024 | Volume: 15 | Issue: 9 | Pages: e1

10.14309/ctg.0000000000000743 | PMID 39320959 Get It

INTRODUCTION: Pharmacologic therapies for symptoms of gastroparesis (GP) have limited efficacy, and it is difficult to predict which patients will respond. In this study, we implemented a machine learning model to predict the response to prokinetics and/or neuromodulators in patients with GP-like symptoms. METHODS: Subjects with suspected GP underwent simultaneous gastric emptying scintigraphy (GES) and wireless motility capsule and were followed for 6 months. Subjects were included if they were started on neuromodulators and/or prokinetics. Subjects were considered responders if their GP Cardinal Symptom Index at 6 months decreased by ≥1 from baseline. A machine learning model was trained using lasso regression, ridge regression, or random forest. Five-fold cross-validation was used to train the models, and the area under the receiver operator characteristic curve (AUC-ROC) was calculated using the test set. RESULTS: Of the 150 patients enrolled, 123 patients received either a prokinetic and/or a neuromodulator. Of the 123, 45 were considered responders and 78 were nonresponders. A ridge regression model with the variables, such as body mass index, infectious prodrome, delayed gastric emptying scintigraphy, no diabetes, had the highest AUC-ROC of 0.72. The model performed well for subjects on prokinetics without neuromodulators (AUC-ROC of 0.83) but poorly for those on neuromodulators without prokinetics. A separate model with gastric emptying time, duodenal motility index, no diabetes, and functional dyspepsia performed better (AUC-ROC of 0.75). DISCUSSION: This machine learning model has an acceptable accuracy in predicting those who will respond to neuromodulators and/or prokinetics. If validated, our model provides valuable data in predicting treatment outcomes in patients with GP-like symptoms.
Reply: Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma
Sharma, Vidit

Journal of Urology | July 8, 2024 | Volume: 212 | Issue: 4 | Pages: 621-622

10.1097/ju.0000000000004136 | PMID 38973728 Get It

Case Report of Hyponatremic Seizures in a Term Neonate Attributed to Excessive Maternal Coconut Water Ingestion During Labor
Soriano, Laura P., Rollins, Mark D. , Chang, Odmara L. Barreto , Soriano, Laura P.

A&A Practice | July 8, 2024 | Volume: 18 | Issue: 7 | Pages: e01815

10.1213/xaa.0000000000001815 | PMID 38975685 Get It

We report the case of a term neonate who was somnolent at birth with ventilatory distress and experienced 2 seizures shortly after delivery. Laboratory tests revealed the neonate had a serum sodium of 113 mmol/L. The seizures stopped after treatment with midazolam, and the sodium was corrected slowly with 3% hypertonic saline without further sequelae. The severe neonatal hyponatremia and seizures were attributed to maternal consumption of excessive amounts of coconut water during labor. This case demonstrates the importance of careful consideration of both fluid volume and fluid electrolyte composition during labor to prevent adverse maternal and neonatal outcomes.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce , Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Lee, Joyce S , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1051-1069

10.1002/acr.25348 | PMID 38973731 Get It

Objective We provide evidence‐based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods We developed clinically relevant population, intervention, comparator, and outcomes questions. A systematic literature review was then performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A panel of clinicians and patients reached consensus on the direction and strength of the recommendations. Results Thirty‐five recommendations were generated (including two strong recommendations) for first‐line SARD‐ILD treatment, treatment of SARD‐ILD progression despite first‐line ILD therapy, and treatment of rapidly progressive ILD. The strong recommendations were against using glucocorticoids in systemic sclerosis–ILD as a first‐line ILD therapy and after ILD progression. Otherwise, glucocorticoids are conditionally recommended for first‐line ILD treatment in all other SARDs. Conclusion This clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the treatment of ILD in people with SARDs.
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson, Sindhu R. , Bernstein, Elana J. , Bolster, Marcy B. , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Allen, Aberdeen, Buckley, Lenore M. , Corwin, Douglas S., Dellaripa, Paul F. , Domsic, Robyn T. , Doyle, Tracy J. , Falardeau, Catherine Marie, Gibbons, Fiona K., Johnson, Cheilonda , Lim, Sian Yik , McMahan, Zsuzsanna H. , Merck, Samantha J. , Nesbitt, Kiana, Scholand, Mary Beth , Shapiro, Lee , Sharkey, Christine D., Summer, Ross , Varga, John , Warrier, Anil, Agarwal, Sandeep K. , Antin‐Ozerkis, Danielle, Chowdhary, Vaidehi , D’Amico, Jane E. Dematte, Hallowell, Robert W. , Hinze, Alicia M. , Injean, Patil, Jiwrajka, Nikhil , Joerns, Elena K. , Lee, Joyce S., Natalini, Jake G. , Saygın, Didem , Lakin, Kimberly S. , Solomon, Joshua J. , Turgunbaev, Marat, Vaseer, Samera, Turner, Amy S. , Uhl, Stacey , Ivlev, Ilya , George, Michael , Khanna, Dinesh , Aggarwal, Rohit , Assassi, Shervin , Buckley, Lenore , Dellaripa, Paul F , Domsic, Robyn T , Frech, Tracy M , Hinchcliff, Monique , Lim, Sian Yik , McMahan, Zsuzsanna H , Hinze, Alicia M , Jiwrajka, Nikhil , Joerns, Elena K , McDermott, Gregory , Natalini, Jake G , Sparks, Jeffrey A , Turner, Amy S , Ivlev, Ilya , Bernstein, Elana J , Chung, Jonathan Hero , Danoff, Sonye Karen , Guyatt, Gordon , Mirza, Reza Donald , Assassi, Shervin , Chami, Hassan A. , Frech, Tracy , Kanne, Jeffrey P. , Kim, John S. , Matson, Scott M. , Bemiss, B. , Makol, Ashima , McDermott, Gregory C , Oldham, Justin M , Singh, Namrata , Sparks, Jeffrey A.

Arthritis Care & Research | July 8, 2024 | Volume: 76 | Issue: 8 | Pages: 1070-1082

10.1002/acr.25347 | PMID 38973729 Get It

ObjectiveWe provide evidence‐based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease.MethodsWe developed clinically relevant population, intervention, comparator, and outcomes questions related to screening and monitoring for ILD in patients with SARDs. A systematic literature review was performed, and the available evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. A Voting Panel of interdisciplinary clinician experts and patients achieved consensus on the direction and strength of each recommendation.ResultsFifteen recommendations were developed. For screening people with these SARDs at risk for ILD, we conditionally recommend pulmonary function tests (PFTs) and high‐resolution computed tomography of the chest (HRCT chest); conditionally recommend against screening with 6‐minute walk test distance (6MWD), chest radiography, ambulatory desaturation testing, or bronchoscopy; and strongly recommend against screening with surgical lung biopsy. We conditionally recommend monitoring ILD with PFTs, HRCT chest, and ambulatory desaturation testing and conditionally recommend against monitoring with 6MWD, chest radiography, or bronchoscopy. We provide guidance on ILD risk factors and suggestions on frequency of testing to evaluate for the development of ILD in people with SARDs.ConclusionThis clinical practice guideline presents the first recommendations endorsed by the American College of Rheumatology and American College of Chest Physicians for the screening and monitoring of ILD in people with SARDs.